Acetylon Pharma Licenses Discovery Methodology, Platform From Harvard, Dana-Farber Cancer Institute
The license also includes a portfolio of small-molecule selective histone deacetylase (HDAC) enzyme inhibitors including the first-ever selective inhibitor of HDAC6. Acetylon is currently focused on the development
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.